PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
In this open-label phase II study, patients will be scheduled for neoadjuvant treatment with
PD-1 antibody following preoperative Chemoradiotherapy with capecitabine for pMMR/MSS rectal
cancer staged as locally advanced (cT3-T4N+/-M0 for rectal cancer). This treatment will be
given during the window period until surgical resection of the tumor.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Fudan University Liaoning Tumor Hospital & Institute